Table 1. Baseline characteristics of the cancer patients.
| Cancer Type | Age (mean±SD) |
Gender (male/female) |
Stage (I/II/III/IV/unavailable) | height (mean±SD) |
weight (mean±SD) |
BMI (mean±SD) |
|---|---|---|---|---|---|---|
| UVM | 61.3±13.7 | 28/25 | 0/17/32/3/1 | 166.5±10.7 | 79.4±22.8 | 28.7±8.9 |
| UCEC | 63.7±11.1 | 0/515 | 322/49/115/29/0 | 161.2±8.2 | 87.7±25.4 | 33.9±12.1 |
| UCS | 69.5±9.2 | 0/52 | 22/5/16/9/0 | 157.7±7.7 | 73.3±20.2 | 29.6±9.0 |
| THYM | 59.1±13.0 | 53/47 | 30/51/13/6/0 | 167.3±11.1 | 76.8±19.6 | 27.3±6.1 |
| SKCM | 59.5±15.3 | 143/99 | 34/89/94/11/14 | 170.1±9.4 | 81.4±19.3 | 28.1±6.1 |
| READ | 60.5±11.7 | 44/31 | 9/20/31/13/2 | 170.7±9.6 | 79.1±22.5 | 26.9±5.8 |
| DLBC | 56.3±14.1 | 21/26 | 8/17/4/12/6 | 164.9±9.1 | 71.0±18.4 | 26.0±5.9 |
| LIHC | 59.5±12.8 | 231/105 | 163/77/76/4/16 | 167.4±10.7 | 73.0±19.6 | 26.2±8.4 |
| KIRP | 61.1±12.0 | 144/46 | 113/13/30/9/25 | 172.1±14.4 | 87.6±21.2 | 32.1±33.3 |
| ESCA | 62.3±11.7 | 151/24 | 18/73/53/9/22 | 172.1±8.6 | 75.1±19.1 | 25.3±5.9 |
| COAD | 64.3±13.1 | 124/108 | 32/93/76/25/6 | 168.4±12.3 | 81.2±20.2 | 29.4±17.2 |
| CHOL | 63.4±12.9 | 16/19 | 19/8/1/7/0 | 167.3±11.7 | 79.2±20.6 | 28.0±5.3 |
| CESC | 48.5±13.5 | 0/258 | 132/62/39/20/5 | 160.8±7.3 | 72.4±19.9 | 28.0±7.7 |
| BLCA | 67.7±10.5 | 267/93 | 2/117/119/120/2 | 171.6±10.2 | 80.3±21.1 | 27.1±6.2 |
| OVERALL | 61.3±13.4 | 1222/1448 | 904/691/699/277/99 | 167.0±11.0 | 79.9±22.0 | 29.0±13.1 |
UVM, Uveal Melanoma; UCEC, Uterine Corpus Endometrial Carcinoma; UCS, Uterine Carcinosarcoma; THYM, Thymoma; SKCM, Skin Cutaneous Melanoma; READ, Rectum adenocarcinoma; DLBC, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; LIHC, Liver hepatocellular carcinoma; KIRP, Kidney renal papillary cell carcinoma; ESCA, Esophageal carcinoma; COAD, Colon adenocarcinoma; CHOL, Cholangiocarcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; BLCA, Bladder Urothelial Carcinoma.